Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Managing Parkinson's disease: moving ON with NOP.

Literature DB >> 31648371

Managing Parkinson's disease: moving ON with NOP.

Daniela Mercatelli¹, Erwan Bezard^2,3, Roberto Eleopra⁴, Nurulain T Zaveri⁵, Michele Morari¹.

Abstract

The opioid-like neuropeptide nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP receptor) contribute to Parkinson's disease (PD) and motor complications associated with levodopa therapy. The N/OFQ-NOP receptor system is expressed in cortical and subcortical motor areas and, notably, in dopaminergic neurons of the substantia nigra compacta. Dopamine depletion, as in rodent models of PD results in up-regulation of N/OFQ transmission in the substantia nigra and down-regulation of N/OFQ transmission in the striatum. Consistent with this, NOP receptor antagonists relieve motor deficits in PD models by reinstating the physiological balance between excitatory and inhibitory inputs impinging on nigro-thalamic GABAergic neurons. NOP receptor antagonists also counteract the degeneration of nigrostriatal dopaminergic neurons, possibly by attenuating the excitotoxicity or modulating the immune response. Conversely, NOP receptor agonists attenuate levodopa-induced dyskinesia by attenuating the hyperactivation of striatal D1 receptor signalling in neurons of the direct striatonigral pathway. The N/OFQ-NOP receptor system might represent a novel target in the therapy of PD.

Entities: Disease Gene

Mesh：

Substances：

Year: 2020 PMID： 31648371 PMCID： PMC6976791 DOI： 10.1111/bph.14893

Source DB: PubMed Journal: Br J Pharmacol ISSN： 0007-1188 Impact factor: 8.739

143 in total

Review 1. Cellular actions of nociceptin: transduction mechanisms.

Authors: B E Hawes; M P Graziano; D G Lambert
Journal: Peptides Date: 2000-07 Impact factor: 3.750

Review 2. The functional anatomy of basal ganglia disorders.

Authors: R L Albin; A B Young; J B Penney
Journal: Trends Neurosci Date: 1989-10 Impact factor: 13.837

3. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors: M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal: Science Date: 1997-06-27 Impact factor: 47.728

4. Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study.

Authors: Anders Bjornestad; Ole-Bjorn Tysnes; Jan Petter Larsen; Guido Alves
Journal: Neurology Date: 2016-09-02 Impact factor: 9.910

5. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.

Authors: B C Tel; B-Y Zeng; C Cannizzaro; R K B Pearce; S Rose; P Jenner
Journal: Neuroscience Date: 2002 Impact factor: 3.590

6. Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding.

Authors: C R Neal; A Mansour; R Reinscheid; H P Nothacker; O Civelli; H Akil; S J Watson
Journal: J Comp Neurol Date: 1999-10-04 Impact factor: 3.215

7. MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons.

Authors: S Gouty; J M Brown; J Rosenberger; B M Cox
Journal: Neuroscience Date: 2010-04-22 Impact factor: 3.590

8. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).

Authors: Paola F Zaratin; Giuseppe Petrone; Massimo Sbacchi; Martine Garnier; Claudia Fossati; Paola Petrillo; Silvio Ronzoni; Giuseppe A M Giardina; Mark A Scheideler
Journal: J Pharmacol Exp Ther Date: 2003-10-30 Impact factor: 4.030

Managing Parkinson's disease: moving ON with NOP.

Review 1. Cellular actions of nociceptin: transduction mechanisms.

Review 2. The functional anatomy of basal ganglia disorders.

3. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

4. Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study.

5. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.

6. Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding.

7. MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons.

8. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).

9. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.

10. In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.

Review 1. Managing Parkinson's disease: moving ON with NOP.

2. µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease.

3. Loss of Corticostriatal Mu-Opioid Receptors in α-Synuclein Transgenic Mouse Brains.